<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691817</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 16520</org_study_id>
    <nct_id>NCT04691817</nct_id>
  </id_info>
  <brief_title>Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy</brief_title>
  <official_title>A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to evaluate the safety and effectiveness of tocilizumab in&#xD;
      combination with atezolizumab to treat non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>From first dose of protocol treatment until radiologic disease assessment at 12 weeks.</time_frame>
    <description>Assess the proportion of patients with a radiologic response by RECIST 1.1 at 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose of protocol treatment until death due to any cause or last patient contact alive until 3 months after study closure.</time_frame>
    <description>Estimate the time from first dose of protocol treatment until death due to any cause or last patient contact alive until 3 months after study closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Limiting Toxicities of the combination</measure>
    <time_frame>From first dose of protocol treatment until 49 days post treatment</time_frame>
    <description>Determine dose limiting toxicities of the combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS).</measure>
    <time_frame>From 1st dose of treatment until 1st radiologic disease progression, unequivocal clinical progression, or death due to any cause censored at the last scheduled disease assessment on study if no progression date registered, assessed up to 24 months.</time_frame>
    <description>Estimate the time from first dose of protocol treatment until first radiologic disease progression, unequivocal clinical progression, or death due to any cause censored at the last scheduled disease assessment on study if there is no progression date registered.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical outcomes</measure>
    <time_frame>From enrollment until dealth due to any cause or last patient contact alive until 3 months after study closure</time_frame>
    <description>Correlate clinical outcomes with potential markers of immune escape and changes in the tumor microenvironment and blood using a novel field theory based methods under development by Cold Spring Harbor Laboratory.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Lung Cancer, Nonsmall Cell</condition>
  <arm_group>
    <arm_group_label>Atezolizumab and Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg/kg IV (or Tocilizumab 4mg/kg IV) every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200mg infusion</description>
    <arm_group_label>Atezolizumab and Tocilizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab 6mg/kg or 4mg/kg infusion</description>
    <arm_group_label>Atezolizumab and Tocilizumab</arm_group_label>
    <other_name>Actemra, RoActemra, RO4877533</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent&#xD;
             therapy) in adults age 18 or older&#xD;
&#xD;
          -  Prior exposure to at least 1 line of therapy&#xD;
&#xD;
          -  Exposure to a including checkpoint inhibitor in line of therapy immediately prior to&#xD;
             enrollment on trial&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a driver mutation that is susceptible to targeted therapy&#xD;
&#xD;
          -  No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy&#xD;
&#xD;
          -  Other active invasive malignancy requiring ongoing therapy&#xD;
&#xD;
          -  Evidence of progressing or untreated brain metastases&#xD;
&#xD;
          -  Evidence or history of leptomeningeal disease&#xD;
&#xD;
          -  Uncontrolled tumor related pain&#xD;
&#xD;
          -  History of an autoimmune disease or IPF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melina Marmarelis, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Volpe, BA</last_name>
    <phone>215-220-9703</phone>
    <email>melissa.volpe@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melina Marmarelis, MD, MSCE</last_name>
    <phone>215-615-5835</phone>
    <email>melina.marmarelis@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mel V, BA</last_name>
      <phone>215-220-9703</phone>
      <email>Melissa.volpe@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Melina Marmarelis, MD, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

